Last 12 months
Inside the activity.
2 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 1 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 10 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2023 Filed Mar 29, 2023 20:05 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 28,000 | $30.80 | $862,400.00 |
DisclosureSEC source: 0000899243-23-009972 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,126,350 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $30.88, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:05 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 32,964 | $30.25 | $997,161.00 |
DisclosureSEC source: 0000899243-23-009972 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,154,350 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.67 to $30.65, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 20:05 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 28,807 | $32.17 | $926,721.19 |
DisclosureSEC source: 0000899243-23-009506 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,187,314 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.005 to $32.38, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 20:05 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 34,641 | $31.69 | $1,097,773.29 |
DisclosureSEC source: 0000899243-23-009506 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,216,121 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $32.00, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:05 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 9,122 | $32.55 | $296,921.10 |
DisclosureSEC source: 0000899243-23-008858 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250,762 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $32.93, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
MILNE GEORGE M JRDirector
|
SaleCommon Stock | 1,916 | $32.45 | $62,171.71 |
DisclosureSEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,021 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.30 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
MILNE GEORGE M JRDirector
|
SaleCommon Stock | 33,084 | $31.86 | $1,053,900.75 |
DisclosureSEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,937 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.30 to $32.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:21 UTC |
Cohen Joshua BDirector · Co-Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009171 · doc4.xml · derivative · entry 4 Cohen Joshua B · CIK 0001898644 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-03-16 F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:21 UTC |
Cohen Joshua BDirector · Co-Chief Executive Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009171 · doc4.xml · nonDerivative · entry 3 Cohen Joshua B · CIK 0001898644 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,842,617 F4 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:21 UTC |
Cohen Joshua BDirector · Co-Chief Executive Officer
|
SaleCommon Stock | 3,924 | $32.45 | $127,314.57 |
DisclosureSEC source: 0000899243-23-009171 · doc4.xml · nonDerivative · entry 2 Cohen Joshua B · CIK 0001898644 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,792,617 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.26 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:21 UTC |
Cohen Joshua BDirector · Co-Chief Executive Officer
|
SaleCommon Stock | 96,076 | $31.84 | $3,059,021.41 |
DisclosureSEC source: 0000899243-23-009171 · doc4.xml · nonDerivative · entry 1 Cohen Joshua B · CIK 0001898644 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,796,541 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:27 UTC |
Olinger MargaretChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009180 · doc4.xml · derivative · entry 2 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-03-16 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:27 UTC |
Olinger MargaretChief Commercial Officer
|
GrantCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009180 · doc4.xml · nonDerivative · entry 1 Olinger Margaret · CIK 0001898725 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,688 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:31 UTC |
Klee Justin B.Director · Co-Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009182 · doc4.xml · derivative · entry 4 Klee Justin B. · CIK 0001898314 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-03-16 F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:31 UTC |
Klee Justin B.Director · Co-Chief Executive Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009182 · doc4.xml · nonDerivative · entry 3 Klee Justin B. · CIK 0001898314 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,842,617 F4 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:31 UTC |
Klee Justin B.Director · Co-Chief Executive Officer
|
SaleCommon Stock | 3,445 | $32.48 | $111,876.72 |
DisclosureSEC source: 0000899243-23-009182 · doc4.xml · nonDerivative · entry 2 Klee Justin B. · CIK 0001898314 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,792,617 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:31 UTC |
Klee Justin B.Director · Co-Chief Executive Officer
|
SaleCommon Stock | 96,555 | $31.84 | $3,074,359.48 |
DisclosureSEC source: 0000899243-23-009182 · doc4.xml · nonDerivative · entry 1 Klee Justin B. · CIK 0001898314 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,796,062 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.32 to $32.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Yeramian Patrick DChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009178 · doc4.xml · derivative · entry 4 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2033-03-16 F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Yeramian Patrick DChief Medical Officer
|
GrantCommon Stock | 9,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 3 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,839 F4 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Yeramian Patrick DChief Medical Officer
|
SaleCommon Stock | 2,416 | $32.43 | $78,358.37 |
DisclosureSEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 2 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,672 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Yeramian Patrick DChief Medical Officer
|
SaleCommon Stock | 52,211 | $31.85 | $1,662,842.03 |
DisclosureSEC source: 0000899243-23-009178 · doc4.xml · nonDerivative · entry 1 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,088 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Mazzariello GinaChief Legal Officer
|
GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009177 · doc4.xml · derivative · entry 2 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-03-16 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC |
Mazzariello GinaChief Legal Officer
|
GrantCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009177 · doc4.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,747 F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:22 UTC |
Firestone KarenDirector
|
GrantStock Option (Right to Buy) · Derivative | 27,403 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009172 · doc4.xml · derivative · entry 2 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,403 Underlying: Common Stock · 27,403 shares Expires 2033-03-16 F2 · derivative.exercise_date: One-third of the shares subject to the option shall vest on the first anniversary of the date of grant, and the remaining two-thirds will vest in equal monthly installments over two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:22 UTC |
Firestone KarenDirector
|
PurchaseCommon Stock | 1,000 | $31.99 | $31,990.00 |
DisclosureSEC source: 0000899243-23-009172 · doc4.xml · nonDerivative · entry 1 Firestone Karen · CIK 0001969821 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.96 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:18 UTC |
FRATES JAMES MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 97,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009168 · doc4.xml · derivative · entry 4 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2033-03-16 F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:18 UTC |
FRATES JAMES MChief Financial Officer
|
GrantCommon Stock | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009168 · doc4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,176 F4 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:18 UTC |
FRATES JAMES MChief Financial Officer
|
SaleCommon Stock | 1,704 | $32.46 | $55,320.19 |
DisclosureSEC source: 0000899243-23-009168 · doc4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,509 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:18 UTC |
FRATES JAMES MChief Financial Officer
|
SaleCommon Stock | 30,796 | $31.86 | $981,139.00 |
DisclosureSEC source: 0000899243-23-009168 · doc4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,213 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,500 Underlying: Common Stock · 32,500 shares Expires 2031-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F7 · derivative.exercise_date: 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 97,500 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · derivative · entry 5 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2033-03-16 F6 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
GrantCommon Stock | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,676 F5 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
SaleCommon Stock | 1,704 | $32.46 | $55,320.19 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,009 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
SaleCommon Stock | 30,796 | $31.86 | $981,139.00 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,713 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:48 UTC Amendment |
FRATES JAMES MChief Financial Officer
|
Exercise / conversionCommon Stock | 32,500 | $6.88 | $223,600.00 |
DisclosureSEC source: 0000899243-23-009602 · doc4a.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,748 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 10 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,252 Underlying: Common Stock · 16,748 shares Expires 2031-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F9 · derivative.exercise_date: 16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,041 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 9 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,466 Underlying: Common Stock · 30,041 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F8 · derivative.exercise_date: As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,789 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 8 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,789 shares Expires 2028-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F7 · derivative.exercise_date: The shares subject to such option are vested and currently exercisable. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $32.08 | $0.00 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · derivative · entry 7 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2033-03-16 F6 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
GrantCommon Stock | 9,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 6 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,417 F5 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
SaleCommon Stock | 2,416 | $32.43 | $78,358.37 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 5 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,250 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
SaleCommon Stock | 52,211 | $31.85 | $1,662,842.03 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 4 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,666 F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionCommon Stock | 16,748 | $6.88 | $115,226.24 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 3 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionCommon Stock | 30,041 | $0.37 | $11,115.17 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 2 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 16, 2023 Filed Mar 24, 2023 22:45 UTC Amendment |
Yeramian Patrick DChief Medical Officer
|
Exercise / conversionCommon Stock | 2,789 | $0.33 | $920.37 |
DisclosureSEC source: 0000899243-23-009600 · doc4a.xml · nonDerivative · entry 1 Yeramian Patrick D · CIK 0001358266 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. F2 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022. F1 · balance_after: On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:11 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 41,066 | $33.68 | $1,383,102.88 |
DisclosureSEC source: 0000899243-23-008733 · doc4.xml · nonDerivative · entry 3 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259,884 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.505 to $34.460, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:11 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 108,934 | $33.12 | $3,607,894.08 |
DisclosureSEC source: 0000899243-23-008733 · doc4.xml · nonDerivative · entry 2 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300,950 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.5 to $33.5, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:11 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 70,714 | $34.54 | $2,442,461.56 |
DisclosureSEC source: 0000899243-23-008733 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,409,884 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $34.88, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 14:10 UTC |
Morningside Venture Investments Ltd10% owner
|
SaleCommon Stock | 50,000 | $33.75 | $1,687,500.00 |
DisclosureSEC source: 0000899243-23-007120 · doc4.xml · nonDerivative · entry 1 Morningside Venture Investments Ltd · CIK 0001543112 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,480,598 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.38 to $34.04, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F2 · ownership.direct: Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards and Cheung Ka Ho, the directors of Morningside Venture Investments Limited ("MVIL"), share voting and dispositive control over the shares held by MVIL. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:42 UTC |
Mazzariello GinaChief Legal Officer
|
SaleCommon Stock | 3,586 | $34.49 | $123,671.82 |
DisclosureSEC source: 0000899243-23-006418 · doc4.xml · nonDerivative · entry 1 Mazzariello Gina · CIK 0001913765 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,414 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.25 to $34.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.